title: Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
abstract: The aim of this study was to examine the effects of a new sustained-release (SR) microsphere formulation of exenatide, DA-3091, on body weight gain and hepatic injury in high fat diet (HFD)-induced obese mice and high sucrose diet (HSD)-induced non-alcoholic fatty liver disease (NAFLD) mice. Then, we determined whether DA-3091 has the potency as a drug for the treatment of metabolic disease. In obese mice, after 8-week treatment, the body weight gain was significantly more suppressed by both 1 mg/kg and 2 mg/kg of DA-3091, monthly subcutaneous administered, than by 10 mg/kg/day of sibutramin, a drug against obesity. In NAFLD mice, a significant reduction in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, representative markers of hepatic injury, was observed after biweekly subcutaneous administration of 1 mg/kg and 2 mg/kg of DA-3091 for 8 weeks. A significant reduction in hepatic lipid accumulation was observed in DA-3091 treated groups as well. Based on these results, it is demonstrated that DA-3091 has the potency as a drug for the treatment of metabolic disease.
authors: College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea. jinpubs@donga.co.kr
authors: Jin Pub
authors: JP
authors: Son
authors: Mi-Kyung
authors: MK
authors: Son
authors: Seoung-Wook
authors: SW
authors: Jun
authors: Hyun-Hee
authors: HH
authors: Kwak
authors: Soo Hyoung
authors: SH
authors: Kang
authors: Jung Seok
authors: JS
authors: Kang
authors: Young In
authors: YI
authors: Park
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003692:Delayed-Action Preparations; D004041:Dietary Fats; D004731:Endotoxins / Q000097:blood; D000077270:Exenatide; D005234:Fatty Liver / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008863:Microspheres; D065626:Non-alcoholic Fatty Liver Disease; D009765:Obesity / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011355:Prodrugs; D013395:Sucrose; D014688:Venoms / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D004041:Dietary Fats; D004731:Endotoxins; D007004:Hypoglycemic Agents; D010455:Peptides; D011355:Prodrugs; D014688:Venoms; D013395:Sucrose; D002784:Cholesterol; D000077270:Exenatide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase